跳至主要内容
临床试验/EUCTR2004-001487-43-GB
EUCTR2004-001487-43-GB进行中(未招募)1 期

A randomised, single-centre, single-blind,parallel group, pilot study to assess the efficacy, safety and patient acceptability of a new 2-litre bowel preparation agent (Moviprep) compared to a standard bowel preparation agent (Picolax) - Moviprep versus Picolax pilot study

orgine Ltd.0 个研究点目标入组 0 人开始时间: 2005年6月15日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • ? written informed consent, obtained prior to inclusion
  • ? male or female, aged 18 to 80 years, inclusive, scheduled to undergo a complete colonoscopy
  • ? willing, able and competent to complete the entire procedure and to comply with study instructions
  • ? females of childbearing potential must employ an adequate method of contraception.
  • ? If an adequate method of contraception is not being used, the patient will be
  • post hysterectomy, post bilateral oophorectomy, post menopause or have any other
  • condition which precludes pregnancy
  • ? females of childbearing potential must undergo a pregnancy test
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • ? gastro-intestinal obstruction or perforation
  • ? toxic megacolon, toxic colitis
  • ? congestive heart failure (New York Heart Association [NYHA] III + IV)
  • ? acute life-threatening cardiovascular disease
  • ? acute surgical abdominal conditions
  • ? untreated or uncontrolled arterial hypertension
  • ? known clinically significant reduced renal function with creatinine > 170 µmol/L
  • ? known clinically significant reduced liver function
  • ? severe uncontrolled inflammatory bowel disease
  • ? known glucose-6-phosphatase dehydrogenase deficiency
  • ? known phenylketonuria
  • ? known hypersensitivity to polyethylene glycols, Vitamin C, sodium picosulphate or magnesium citrate
  • ? concurrent participation in an investigational drug study or participation within 30 days of study entry
  • ? administration of any other investigational or unapproved drug, or any other product known to cause gut cleansing (for example, Golytely, Golytely RSS, saline laxatives, strong laxatives, enemas) on Day 7 or 8 until after the colonoscopy.
  • ? administration of ferrous supplements 1 week prior to their colonoscopy
  • ? females who are pregnant, nursing or planning a pregnancy, or females of child-bearing potential not using reliable methods of contraception
  • ? patient has a condition, clinically significant laboratory results or is in a situation which, in the investigator’s opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly; this includes laboratory results.

研究者

发起方
orgine Ltd.

相似试验